Dual vs single protease inhibitor therapy following antiretroviral treatment failure: A randomized trial

Journal of the American Medical Association

Volumn 288, Issue 2, 2002, Pages 169-180

  Hammer, Scott M ^a   Vaida, Florin ^b   Bennett, Kara K ^b   Holohan, Mary K ^c   Sheiner, Lewis ^d   Eron, Joseph J ^e   Wheat, Lawrence Joseph ^o   Mitsuyasu, Ronald T ^f   Gulick, Roy M ^g   Valentine, Fred T ^h   Aberg, Judith A ^d   Rogers, Michael D ^j   Karol, Cheryl N ^k   Saah, Alfred J ^l   Lewis, Ronald H ^m   Bessen, Laura J ^n,q   Brosgart, Carol ^p   DeGruttola, Victor ^b   Mellors, John W ⁱ  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c AIDS Clinical Trial Group Operations Center   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h NEW YORK UNIVERSITY   (United States)

ⁱ UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^j Hoffman LaRoche ^*  (United States)

^k HOFFMANN LA ROCHE INC   (United States)

^l MERCK RESEARCH LABORATORIES   (United States)

^m AGOURON PHARMACEUTICALS INC   (United States)

ⁿ DUPONT COMPANY   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p GILEAD SCIENCES   (United States)

^q BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR DIPIVOXIL; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ; INDINAVIR; NELFINAVIR; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; LEUKOCYTE COUNT; MALE; MULTICENTER STUDY; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; VIRUS INFECTION; VIRUS LOAD;

EID: 0037055027     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.2.169     Document Type: Article

References (78)

1. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
2. AIDS across Europe, 1994-98
3. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
4. Anti-retroviral therapy in adults
5. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
6. Abacavirlamivudine-zidovudine vs indinavir-lamivudinezidovudine in antiretroviral-naive HIV-infected adults
7. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
8. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
9. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic
10. Highly active antiretroviral therapy in a large urban clinic
11. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
12. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors
13. Antiretroviral therapy for previously treated patients
14. Antiretroviral drug resistance testing in adult HIV-1 infection
15. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir
16. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen
17. HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients
18. Relationship of phenotypic and genotypic resistance profiles to virological outcome in a trial of abacavir, nelfinavir, efavirenz and adefovir dipivoxil in patients with virological failure receiving indinavir (ACTG 372)
19. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir
20. Drug-resistance genotyping in HIV-1 therapy
21. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
22. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy
23. Clinical utility of HIV-1 genotyping and expert advice
24. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy
25. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
26. Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks
27. Dose-finding study of a once-daily indinavir/ritonavir regimen
28. Ritonavir
29. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
30. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease
31. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients
32. A phase II trial of dual protease inhibitor therapy
33. Amprenavir
34. Amprenavir
35. Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors
36. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy
37. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
38. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine
39. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy
40. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy
41. HIV-protease inhibitors
42. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects
43. Prevalence and predictive value of intermittent viremia with combination HIV therapy
44. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
45. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
46. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
47. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
48. Non-nucleoside reverse transcriptase inhibitor viral hypersensitivity is common and improves short term virologic response
49. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients
50. Worldwide variation in HIV-1 phenotypic susceptibility in untreated individuals
51. Linear regression with censored data
52. The relation between baseline HIV drug resistance and response to antiretroviral therapy
53. What's the relative risk? a method of correcting the odds ratio in cohort studies of common outcomes
54. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir
55. Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients
56. Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy
57. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients
58. A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial
59. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy
60. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults
61. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients
62. Determination of a clinically relevant phenotypic resistance "cut-off" for abacavir using the PhenoSense assay
63. Can early failure with nevirapine (NVP)-based regimens be rescued by replacing NVP with efavirenz
64. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy
65. Adefovir for the treatment of HIV infection
66. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy) propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults
67. Tenofovir disoproxil fumarate (TDF) for the treatment of antiviral experienced patients
68. Metabolism of amprenavir in liver microsomes
69. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir
70. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection
71. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens
72. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure
73. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
74. Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection
75. A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection
76. ABT-378/nitonavir and efavirenz